Access TOC
Download Data
December 2024
The global multiomics market size is calculated at US$ 2.76 in 2024, grew to US$ 3.18 billion in 2025, and is projected to reach around US$ 11.46 billion by 2034. The market is expanding at a CAGR of 15.32% between 2024 and 2034. Multiomics is in high demand due to its significant use in studying various diseases and developing new therapeutics to provide better cures.
Unlock Infinite Advantages: Subscribe to Annual Membership
Across several biological levels, multiomics (multiple omics) offers an integrated method for power discovery. Genomic, transcriptomic, epigenetic, and proteomic data may be combined to give researchers a more complete picture of the molecular alterations underlying illness, cellular response, and normal development. Presently, multiomics has the potential to close knowledge gaps about human health and illness, and several researchers are developing methods for producing and evaluating data pertaining to disease. Applications include enhancing customized therapy, better comprehending chronic and complicated non-communicable illnesses, and understanding host-pathogen interactions, infectious diseases, and cancer.
A potent method for resolving intricate issues in the processing, analysis, and interpretation of omics data, as well as the integration of multi-omics and clinical data, is artificial intelligence (AI). Significant advances in a variety of scientific domains, including drug development, illness diagnostics, protein structure prediction, and genetic variant interpretation, have been made possible in recent years by artificial intelligence.
For instance,
Studying Human Diseases
Generally speaking, multi-omics refers to the cross-cutting use of several high-throughput screening technologies, such as genomics, transcriptomics, single-cell transcriptomics, proteomics and metabolomics, spatial transcriptomics, and so forth, which are very important for advancing the study of human problems. Differently expressed disease-associated molecules from each form of omics data may be used as biomarkers to track the course of a disease and reveal which biological pathways or processes are different in diseased and control groups.
Lack of Proper Approach
One of the main principles of the big data-driven approach to biological research is the integrated computer analysis of multi-omics data. However, there are presently no universally applicable gold standards for assessing and categorizing integration approaches in multi-omics research. More significantly, the development of innovative computational techniques for multi-omics analysis is facing new difficulties due to the absence of a unified or universal approach to big data integration.
Personalized Medicine
With the introduction of novel targeted treatments and the use of sequencing technology breakthroughs that have significantly increased the accuracy of genetic data, personalized medicine has lately made encouraging progress. Beyond genomes, recent developments in multiomics technology have created additional precision medicine prospects that can provide accurate diagnosis and individualized care.
By product & service, the product segment held the largest share of the multiomics market in 2023 and is expected to grow at the fastest rate during the forecast period. Multiomics products consist of instruments, consumables, and software. These products are highly essential for conducting experiments, analyzing data, and understanding the data. Each component is highly essential and hence is in high demand.
By type, the bulk multiomics segment dominated the multiomics market in 2023. The advancement of sequencing technology has led to the creation of several bulk and single-cell profiling techniques that are used in a wide range of biological and clinical studies. Through the use of bulk sequencing techniques, each sample may be clarified at the level of the cell population, yielding the average profile of many cells. In order to gain a thorough grasp of biological activities, bulk multiomics analyses—such as multidimensional genomic and proteogenomic analyses—have recently shown promise.
By type, the single-cell multiomics segment is expected to grow at a significant rate in the multiomics market during the forecast period. Single-cell resolution measurement of DNA, mRNA, and protein profiles is now possible because of recent developments in single-cell isolation and barcoding technology. The technologies of single-cell isolation, barcoding, and sequencing to measure different kinds of molecules from the same cells, as well as integrative analysis of the molecules measured at the single-cell level to identify cell types and their functions related to pathophysiological processes based on the molecular signatures, are the fundamental elements of single-cell multiomics analysis.
For instance,
By platform, the genomics segment captured the largest share of the multiomics market in 2023. An emerging field of medicine called "genomic medicine" uses a patient's genetic information to influence clinical treatment. Infectious disorders, uncommon and undetected illnesses, pharmacology, and cancer are already being impacted by genomic medicine. Genomics has many uses, including the identification of genes, the diagnosis of rare diseases, the identification of genes linked to common diseases, targeted therapy, pharmacogenetics, prenatal diagnosis, personalized medicine, infection research, genome editing, and gene therapy.
By platform, the metabolomics segment is estimated to achieve a significant growth rate in the multiomics market during 2024-2034. A developing technology called metabolomics, which is the thorough examination of metabolites in a biological material, has the potential to guide precision medicine. Modern metabolomic technologies can precisely analyze hundreds to thousands of metabolites, and they are far more advanced than conventional clinical chemistry methods. Consequently, metabolic phenotypes may be thoroughly characterized thanks to metabolomics. On a number of levels, it can facilitate precision medicine, such as the identification of novel therapeutic targets, the characterization of metabolic abnormalities that underlie illness, and the identification of biomarkers that might be utilized for disease diagnosis or treatment activity monitoring.
By application, the oncology segment was dominant in the multiomics market in 2023, and the segment is anticipated to grow at the fastest CAGR during the predicted timeframe. To get a deeper understanding of the molecular and clinical characteristics of malignancies, multi-omics techniques are innovative frameworks that combine several omics datasets produced by the same individuals. There are now previously unheard-of possibilities to further categorize cancers into subtypes, enhance the prognosis and treatment results of these subtypes, and comprehend important pathophysiological processes through various molecular layers thanks to a variety of emerging omics and multi-view clustering algorithms.
By end-use, the academic & research institutes segment held the major share of the multiomics market in 2023. Public and private research institutions share the fundamental goal of advancing society via the rigorous research of their faculty and graduate students. To do this, a research institution can provide its students with top-notch faculty, considerable research money, and cutting-edge research capabilities.
By end-use, the pharmaceutical & biotechnology companies segment is expected to grow at a significant rate in the multiomics market during the forecast period. Multiomics holds a large scope in disease analysis and the development of novel therapeutics. Pharmaceutical and biotechnology companies are well aware of the advantages of integrating multiomics into their processes. Hence, these industries are continuously investing in multiomics to gain more insights into diseases and their cures.
North America dominated the multiomics market in 2023 due to the existence of important actors, industry-research community interactions, and investments in multi-omics applications. Moreover, the region's growing chronic illness rate contributes to the expansion of the multiomics industry. For example, according to data released by the Canadian Cancer Society (CCS), there were about 239,100 new cases of cancer in Canada in 2023, with a 20% fatality rate. Additionally, the market in the area is driven by the growth of laboratories by major firms to meet the need for multi-omics. The single-cell multi-omics solutions supplier Singleton, for example, increased its footprint in Michigan, the United States, in February 2024 by opening a new office and labs.
Asia Pacific is estimated to host the fastest-growing multiomics market during the forecast period. Due to its substantial development potential, the Asia-Pacific market may expand at the fastest rate. For countries like China, Japan, and India, developing genomics and healthcare IT infrastructure is an ongoing undertaking. Since the expansion of multi-omics also depends on the integration of enormous multi-dimensional datasets, this is a complement. In the Asia-Pacific region, the biotech and healthcare industries are expanding concurrently. Regional actors in the multiomics sector are actively looking for technical transfers and research cooperation. Furthermore, the multiomics industry in India grew at the quickest rate in the Asia-Pacific area, while the multiomics market in China had the greatest market share.
For instance,
In October 2024, a strategic alliance was established between Singleton Biotechnologies, a pioneer in single-cell multi-omics solutions, and Bioscreen, a well-known distributor of cutting-edge life science products in India. This deal would make Bioscreen the only distributor of Singleron's state-of-the-art single-cell multi-omics products in India.
By Product & Service
By Type
By Platform
By Application
By End-use
By Region
December 2024
December 2024
December 2024
December 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts